Fact Source: Financial Supervisory Service DART
💡 3-Second Summary
Samsung Biologics has extended both the contract period and the confidentiality withholding deadline for disclosing its counterparty regarding a KRW 91.4B letter of intent (LOI) for a biopharmaceutical contract manufacturing agreement to June 30, 2024, following consultations with the client.
📊 [Key Disclosure Details & Financial Figures]
- Reason for Correction: Extension of contract period and confidentiality withholding date following consultation with the customer
- Pre-correction Contract Period & Withholding Expiration Date: 2021-10-30 ~ 2024-03-31 / 2024-03-31
- Post-correction Contract Period & Withholding Expiration Date: 2021-10-30 ~ 2024-06-30 / 2024-06-30
- Subject: Execution of Letter of Intent (LOI) for Biopharmaceutical Contract Manufacturing Agreement
- Counterparty: European pharmaceutical company (Withheld due to business confidentiality)
- Contract Value: KRW 91,369,732,137 (Confirmed USD 76,703,939, up USD 20,122,939 from USD 56,581,000 / Applied Exchange Rate: USD/KRW 1,191.20)
- Ratio to Recent Annual Revenue: 7.84% (Recent Annual Revenue: KRW 1,164,776,873,641)
- LOI Execution Date: October 30, 2021
- Initial Disclosure Date: December 23, 2021 (Disclosed upon fulfillment of specific contract conditions)
- Other Remarks: The contract value is legally binding between both parties; confirmed terms and counterparty details will be disclosed upon execution of the main contract
📝 Editor’s Comment (Key Follow-up Checkpoint)
📌 Monitoring Main Contract Execution and Counterparty Disclosure Following Period Extension
This correction disclosure reports a three-month extension (from March 31, 2024 to June 30, 2024) of the contract term and confidentiality withholding deadline for the biopharmaceutical contract manufacturing LOI signed in 2021. Tracking whether this letter of intent progresses into a definitive main contract and whether withheld counterparty details are unveiled upon the extended expiration date is essential to understand the progress of the transaction. Investors can verify subsequent developments through future correction disclosures or official Sales/Supply Contract Execution filings.
📢 Disclaimer and Source Notice
Source: This content was structured and newly generated based on official submission data from the Financial Supervisory Service DART system.
Investment Risk Warning: This content is provided solely for informational and linguistic reference purposes. Under no circumstances does it constitute financial advice or a recommendation to buy or sell any security. All investment decisions and financial liabilities rest entirely with the individual investor.
Contact: For regulatory compliance inquiries or copyright concerns, please contact ksb220805@gmail.com.
